ArticleThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
Transforming Growth Factor-β Drives Epithelial Mesenchymal Transition and Reduces Synthesis of Unelaborated O-GalNAc Glycans in Breast Cancer Cells.
Article in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SummaryAltered O-glycosylation of cancer cells is frequently associated with metastasis and poor prognosis. During metastasis, cells must also lose their epithelial characteristics and become mesenchymal and motile, termed epithelial-mesenchymal transition (EMT). While it is established that transforming growth factor beta-1 (TGF-β1) can induce EMT, the effect of cytokine-induced EMT on O-glycosylation of breast cancer cells has not previously been explored. MCF-7 and T47-D breast cancer cells were treated with TGF-β1 over a time course of up to 7 days. Morphological changes were assessed using confocal microscopy and quantified; levels of EMT marker expression were assessed using immunofluorescence with confocal microscopy and western blot. The effect of TGF-β1 on synthesis of unelaborated Tn antigen was explored using
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.